Text Size

The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis (EPO-ProgMS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Rigshospitalet, Denmark.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Danish Research Centre for Magnetic Resonance, Hvidovre.
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT01144117
First received: June 7, 2010
Last updated: August 4, 2011
Last verified: May 2010
History of Changes

June 7, 2010
August 4, 2011
November 2009
December 2012   (final data collection date for primary outcome measure)
The primary outcome measure is the change from baseline to 24 weeks in a composite of maximum gait distance, 9-hole peg test, TRAIL making B comparing the placebo-treatment group with the EPO-treatment group. [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01144117 on ClinicalTrials.gov Archive Site
  • Comparisons between the placebo-and the EPO-group regarding:difference in maximum gait distance between baseline and week 24. [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Comparisons between the placebo-and the EPO-group regarding:difference in 9-hole peg test [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  • Comparisons between the placebo-and the EPO-group regarding:difference in TRAIL making B [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis

In a double-blind, placebo-controlled, parallel group trial, recombinant human erythropoietin (rhEPO) (48000 IU) treatment or placebo will be administered weekly i.v. for 24 weeks: weekly for 12 weeks and bi-weekly for 12 weeks. Methylprednisolone (MP) 1 g i.v. will be administered before the first and second EPO/placebo administration. The 24-week treatment period will be followed by a 24-week observation period.

Patients with primary progressive MS or secondary progressive MS without relapses during the last 1 year will be suitable for the trial. In all 56 patients will be enrolled into the study.

The primary outcome measure is the change from baseline to 24 weeks in a composite of maximum gait distance, 9-hole peg test, TRAIL making B comparing the placebo-treatment group with the EPO-treatment group.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Multiple Sclerosis (Primary or Secondary Progressive Phase).
Drug: Erythropoietin
Erythropoietin 48000 IU given I.V. in 17 courses
Other Name: Epo, NeoRecormon
Experimental: Erythropoietin
Erythropoietin treated patients contra placebo.
Intervention: Drug: Erythropoietin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
56
April 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • age between 19 and 60 years
  • primary progressive MS or secondary progressive MS without relapses during the last one year
  • duration of the disease of at least 2 years Clinical disability progression should have been observed in the 2 years prior to screening as per clinical judgment of the investigator. In addition, progression must be documented by an increase in the EDSS score of at least 0.5 points at any time during the 2 years prior to Screening; or progression of 1 point in the pyramidal, cerebellar, brain stem , visual or sensory functional system during the last 2 years. Should documented EDSS scores not be available, a written summary of the clinical evidence of disability progression in the previous 2 years must be submitted (for example walking distance or hand function).
  • EDSS (Expanded Disability Status Scale) 4.0-6.5
  • MRI fulfilling the Barkhof criteria for MS
  • written informed consent

Exclusion Criteria:

  • pregnancy or period of breastfeeding or missing adequate contraceptive protection
  • treatment with steroids in the last 30 days
  • treatment with interferons, glatiramer acetate or IVIG in the last1 month prior to enrolment
  • treatment with azathioprin, mitoxantrone or any other immuno-suppressive in the 6 months prior to enrolment
  • cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, instable or advanced ischemic heart disease (CCS III or IV), malignant hypertension (systolic > 180, diastolic > 110)
  • history of any haematological disorder
  • history of renal insufficiency
  • any medical psychiatric or other circumstances which impede or restrict the subjects participation in the study in the manner intended
  • contraindication for contrast enhanced MRI (e.g. pace maker, aortic clip or any metal implant)
Both
19 Years to 60 Years
No
Contact: Karen Schreiber, M.D., Ph.d. +45 35 45 98 40 karen.schreiber@rh.dk
Denmark
 
NCT01144117
EudraCT number: 2009-011516-37
Yes
Professor Per Soelberg Sorensen, Rigshospitalet., The Danish MS Research Center
Rigshospitalet, Denmark
Danish Research Centre for Magnetic Resonance, Hvidovre.
Principal Investigator: Karen Schreiber, MD., Ph.d. Rigshospitalet, Denmark
Study Director: Per S Soerensen, MD., Prof Rigshospitalet, Denmark
Rigshospitalet, Denmark
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP